argenx SE (FRA:1AEA)

Germany flag Germany · Delayed Price · Currency is EUR
695.00
-10.00 (-1.42%)
At close: Jan 23, 2026
13.01%
Market Cap43.07B +14.1%
Revenue (ttm)3.14B +93.0%
Net Income1.31B
EPS19.83
Shares Outn/a
PE Ratio32.96
Forward PE27.97
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume1
Open695.00
Previous Close705.00
Day's Range695.00 - 695.00
52-Week Range454.00 - 810.00
Betan/a
RSI48.68
Earnings DateFeb 25, 2026

About argenx SE

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren’s disease, lupus nephropathy, systemic sclerosis, ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2008
Employees 1,599
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 1AEA
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements